Navigation Links
Cardio3 BioSciences Reports Positive Three-Month Data From its Clinical Trial of C-Cure(R) in Heart Failure
Date:6/29/2010

votal clinical program for C-Cure. Cardio3 BioSciences is continuing to take the steps to bring to patients this new treatment for a condition where current therapies do not address the underlying cause of the disease."

Dr. Jozef Bartunek, Associate Director of the Cardiovascular Center in Aalst, Belgium and Co-Principal Investigator of the C-Cure trial commented: "C-Cure could represent a major breakthrough in the field of cardiac regenerative medicine offering the potential of a life-saving treatment potentially avoiding the need for heart transplants. This trial represents a "first-in-man" therapy using cells 'programmed' to become heart cells. The early stage data that we have seen are encouraging and provides us with very valuable insights that we can use in the design of larger studies to fully examine the efficacy of C-Cure in heart failure patients."

The current C-Cure study is a randomised, prospective, multi-center trial to evaluate the safety and efficacy of C-Cure beyond optimal clinical care in patients with heart failure. It recruited 45 patients in Belgium and Serbia. The primary end point of the trial is change in left ventricular ejection fraction (a measure of how well the heart is functioning) at six months post treatment.

Using the insights from the trial and input from regulators in Europe and the US, Cardio3 BioSciences is now designing a pivotal clinical trial program for C-Cure expected to start in 2011. With the Phase II stage completed and to allow for potential modifications to the trial protocol, Cardio3 BioSciences will not continue recruitment into the existing trial but will continue to gather all data for the six month analysis.

About Cardio3 BioSciences


'/>"/>
SOURCE Cardio3 BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
2. Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure
3. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
4. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
5. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
8. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
10. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
11. Pressure BioSciences, Inc. Issued First Patent in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  MiMedx Group, Inc. (NASDAQ: MDXG ... tissue and patent-protected processes to develop and market advanced ... Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, ... th Annual Canaccord|Genuity Growth Conference in ... and CEO, William C. Taylor , President and ...
(Date:8/3/2015)... DOVER, Delaware , August 3, 2015 ... engaged in the commercialization of its Bio-electrical Signal Therapy ... the noninvasive treatment of hard to heal chronic wounds, ... distribution agreement with Chemipal, an Israeli distributor specializing in ... BST device. Chemipal is a 70 years ...
(Date:7/31/2015)... July 31, 2015 In today,s fast ... help them drive positive health outcomes, improve profitability ... of patient care in their communities. At ThoughtSpot ... and conference, AmerisourceBergen announced a new set of ... Administration Organization and help independent pharmacies endure the ...
(Date:7/30/2015)... AACC welcomed thousands of medical professionals ... Meeting & Clinical Lab Expo in ... showcased revolutionary advancements in clinical testing technology and ... to diagnose patients quickly and accurately and make ... As of Wednesday, July 29, more than ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... will potentially enable access to MRI exams for ... implantable cardiac ... Boston,Scientific Corporation (NYSE: BSX ) and Surgi-Vision, ... development arrangement for,magnetic resonance imaging (MRI)-safe technology. Physician implanters ...
... ... 2008, FT. MYERS, Fla., April 15 ... the,Securities and Exchange Commission its annual report on Form 10-KSB for the,year ended ... http://www.SEC.gov ., The audited financial statements for the year ended December ...
... April 15 Arpida Ltd.,(SWX: ARPN) today announced ... Thursday,17 April 2008 at 8.30am CET. In this ... need and developments in the area of anti-infective,drugs ... meeting of the Anti-Infective,Drugs Advisory Committee. During that ...
Cached Biology Technology:Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 2Boston Scientific and Surgi-Vision Announce Licensing Agreement for MRI-Safe Technology 3NeoGenomics Files Annual Report on Form 10-KSB with the SEC 2Arpida Announces Conference Call on 17 April 2Arpida Announces Conference Call on 17 April 3
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... be placing their unborn children at increased risk of ... of construction workers in the Netherlands, conducted in part ... low birth weight and birth defects to paternal, airborne ... cleansers. , The study, although preliminary in its parent-reported ...
... on the eyes" may hit closer to the mark than ... the University of California, San Diego, and published in the ... depend on mental processing ease, or being "easy on the ... what your mind has been trained on," Winkielman said. "A ...
... human infants have located the source of a 30-year-old mystery ... , Scientists have known of the mouse line's naturally occurring ... of Medicine in St. Louis are the first to identify ... and the origins of the disease. , "The gene ...
Cached Biology News:Solvent exposure linked to birth defects in babies of male painters 2Beauty and the brain 2Beauty and the brain 3Scientists solve 30-year-old mystery of mutant mouse's kidney woes 2Scientists solve 30-year-old mystery of mutant mouse's kidney woes 3